https://www.selleckchem.com/pr....oducts/2-2-2-tribrom
1mmHg (FCBT, n = 62) and - 3.5mmHg (FCBT + BIM, n = 15), respectively (both P 0.0001). Patients who achieved target IOP reduction with FCBT did so in 1month (median). VF progression rates were 0.17%/year (FCBT, P = 0.8367) and - 0.08%/year (FCBT + BIM, P = 0.941. Ocular treatment-emergent adverse events occurred in 42.5% (FCBT) and 71.0% (FCBT + BIM) of patients; most were mild and included ocular hyperemia (9.2% and 41.9%, respectively). Despite low mean baseline IOP, ≥ 20% IOP reduction from baseline persisted ove
Like
Comment
Share
